 |
|
Lansoprazole Compared With Ranitidine for the Treatment of Nonerosive Gastroesophageal Reflux Disease
Joel E. Richter, MD;
Donald R. Campbell, MD;
Peter J. Kahrilas, MD;
Bidan Huang, PhD;
Cheryl Fludas, MS
Arch Intern Med. 2000;160:1803-1809.
Background Traditionally, proton pump inhibitors are used primarily for patients with esophagitis. However, patients with nonerosive reflux disease may also benefit from these powerful medications.
Objective To compare the safety and symptom relief efficacy of lansoprazole with ranitidine therapy and with placebo.
Methods In 2 randomized, double-blind, multicenter trials of 901 patients with symptomatic reflux disease, which was confirmed by endoscopy to be nonerosive, received lansoprazole, 15 or 30 mg once daily; ranitidine, 150 mg twice daily; or placebo for 8 weeks.
Results Analysis of daily diary data during the first 4 weeks and for the entire 8 weeks of treatment revealed that patients who were treated with either dosage of lansoprazole reported significantly (P<.05) lower percentages of days and nights with heartburn, less pain severity of both day and night heartburn, fewer days of antacid use, and smaller amounts of antacid use compared with patients who were treated with ranitidine or placebo. The incidence of possible or probable treatment-related adverse reactions was comparable among the treatment groups; abdominal pain and diarrhea were the most commonly reported adverse events. No statistically significant differences were noted between treatment groups in laboratory analyses.
Conclusion Lansoprazole therapy is more effective than standard dosages of ranitidine or placebo in relieving symptoms in patients with endoscopically confirmed nonerosive reflux esophagitis.
From the Cleveland Clinic, Cleveland, Ohio (Dr Richter); Department of Veterans Affairs Medical Center, St Luke's Hospital, University of Missouri, Kansas City (Dr Campbell); Department of Gastroenterology, Northwestern University Medical School, Chicago, Ill (Dr Kahrilas); Abbott Laboratories, Abbott Park, Ill (Dr Huang); and TAP Holdings Inc, Deerfield, Ill (Ms Fludas).
RELATED ARTICLES
Efficacy of Omeprazole for the Treatment of Symptomatic Acid Reflux Disease Without Esophagitis
Joel E. Richter, David Peura, Stanley B. Benjamin, Bo Joelsson, and James Whipple
Arch Intern Med. 2000;160(12):1810-1816.
ABSTRACT
| FULL TEXT
Archives of Internal Medicine Reader's Choice: Continuing Medical Education
Arch Intern Med. 2000;160(12):1879-1880.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
A Systematic Review and Meta-Analysis of the Sex Ratio for Barrett's Esophagus, Erosive Reflux Disease, and Nonerosive Reflux Disease
Cook et al.
Am J Epidemiol 2005;162:1050-1061.
ABSTRACT
| FULL TEXT
Assessment of reflux symptom severity: methodological options and their attributes
Bytzer
Gut 2004;53:iv28-iv34.
ABSTRACT
| FULL TEXT
Obstacles to answering doctors' questions about patient care with evidence: qualitative study
Ely et al.
BMJ 2002;324:710-710.
ABSTRACT
| FULL TEXT
Lansoprazole for Nonerosive Reflux Disease?
JWatch Gastroenterology 2000;2000:2-2.
FULL TEXT
|
